Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease

Neurochem Int. 2006 Apr;48(5):329-40. doi: 10.1016/j.neuint.2005.11.008. Epub 2006 Jan 6.

Abstract

6-Hydroxydopamine (6-OHDA) is widely used to produce animal models of Parkinson's disease (PD) by selectively destroying the nigro-striatal dopaminergic systems, but selective toxicity of 6-OHDA towards dopaminergic cells in vitro remains controversial. Mutant (A30P and A53T) alpha-synuclein isoforms cause increased vulnerability of cells towards various toxic insults and enhance dopamine transporter (DAT)-mediated toxicity of the selective dopaminergic neurotoxin and mitochondrial complex I inhibitor MPP(+) in vitro. Here we extend our recent studies on DAT-mediated toxicity to elucidate the mechanisms involved in selective dopaminergic toxicity of 6-OHDA. We studied the cytotoxicity as well as the toxic mechanisms of 6-OHDA in human embryonic kidney HEK-293 cells ectopically co-expressing mutant alpha-synucleins and the human DAT protein. 6-OHDA showed half-maximal toxic concentration (TC(50)) of 88 microM in HEK-hDAT cells without alpha-synuclein expression after 24 h, whereas the TC(50) values significantly decreased to 58 and 39 microM by expression of A30P and A53T alpha-synuclein, respectively. alpha-Synuclein expression did not affect 6-OHDA toxicity in HEK-293 cells not expressing the DAT. Analysis of intracellular parameters of cellular energy metabolism revealed that the co-expression of mutant alpha-synucleins in HEK-hDAT cells accelerates the reduction of intracellular net ATP levels and ATP/ADP ratios induced by 6-OHDA. Uptake function of the DAT was not altered by expression of alpha-synuclein isoforms. Our data suggest a mechanism of 6-OHDA-induced dopaminergic toxicity involving an interaction of mutant alpha-synucleins with the DAT molecule and subsequent acceleration of cellular energy depletion that might be relevant for the pathogenesis of PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Cell Line
  • Dopamine / metabolism*
  • Dopamine Plasma Membrane Transport Proteins / drug effects*
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Dose-Response Relationship, Drug
  • Energy Metabolism / drug effects
  • Energy Metabolism / physiology
  • Humans
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Mutation / genetics
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurotoxins / toxicity
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology
  • Oxidopamine / toxicity*
  • Parkinson Disease / metabolism*
  • Parkinson Disease / physiopathology
  • Protein Isoforms / drug effects
  • Protein Isoforms / metabolism
  • Sympatholytics / toxicity
  • alpha-Synuclein / genetics*
  • alpha-Synuclein / metabolism*

Substances

  • Dopamine Plasma Membrane Transport Proteins
  • Neurotoxins
  • Protein Isoforms
  • Sympatholytics
  • alpha-Synuclein
  • Oxidopamine
  • Adenosine Triphosphate
  • Dopamine